Fungal infection can be categorized into superficial and deep fungal infection. Since superficial infection is strongly infectious and caused by sorts of dermatophytosis fungi which mainly invade skin, hair and nails, it is common and prevalent with its number of cases occupying 90% of total cases of fungal infection. As a result of mass use of antibiotics and other drugs as well as degradation of internal and external environments, human body’s immune system has weakened and the incidence of fungal infection especially systemic fungal infection has kept increasing. Therefore, the development of antifungal drugs is increasingly valued.
As clotrimazole is sold at a relatively low price, it grows fast despite a small market scale. Ever since its first entry into China, clotrimazole develops rapidly with annual sales value rising from CNY 11.64 million in 2005 to CNY 39.22 million in 2014 and CAGR being 35.48% during this period. Clotrimazole in the Chinese market mainly come from the following top5 companies: Xianju Pharma, Jinan Limin Pharmaceutical Co., Ltd, Jean-Marie Pharmacal Co., Ltd, Bayer Group (Germany) and Guangzhou Baiyunshan Hejigong Pharmaceutical Factory which take up over 90% of the clotrimazole market in China.
Readers can get at least the following information through this report:
-market size of clotrimazole in China
-major manufacturers of clotrimazole in Chinese market and their market share
-retail price of clotrimazole in Chinese market
-market outlook of clotrimazole in China
The author suggests the following groups of people purchase this report:
-manufacturers of antifungal drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service